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Magnetic resonance imaging-based markers of schizophrenia have been repeatedly shown to separate patients from healthy con-
trols at the single-subject level, but it remains unclear whether these markers reliably distinguish schizophrenia from mood
disorders across the life span and generalize to new patients as well as to early stages of these illnesses. The current study used
structural MRI-based multivariate pattern classiﬁcation to (i) identify and cross-validate a differential diagnostic signature separat-
ing patients with ﬁrst-episode and recurrent stages of schizophrenia (n = 158) from patients with major depression (n = 104); and
(ii) quantify the impact of major clinical variables, including disease stage, age of disease onset and accelerated brain ageing on the
signature’s classiﬁcation performance. This diagnostic magnetic resonance imaging signature was then evaluated in an independent
patient cohort from two different centres to test its generalizability to individuals with bipolar disorder (n = 35), ﬁrst-episode
psychosis (n = 23) and clinically deﬁned at-risk mental states for psychosis (n = 89). Neuroanatomical diagnosis was correct in 80%
and 72% of patients with major depression and schizophrenia, respectively, and involved a pattern of prefronto-temporo-limbic
volume reductions and premotor, somatosensory and subcortical increments in schizophrenia versus major depression. Diagnostic
performance was not inﬂuenced by the presence of depressive symptoms in schizophrenia or psychotic symptoms in major de-
pression, but earlier disease onset and accelerated brain ageing promoted misclassiﬁcation in major depression due to an increased
neuroanatomical schizophrenia likeness of these patients. Furthermore, disease stage signiﬁcantly moderated neuroanatomical
diagnosis as recurrently-ill patients had higher misclassiﬁcation rates (major depression: 23%; schizophrenia: 29%) than ﬁrst-
episode patients (major depression: 15%; schizophrenia: 12%). Finally, the trained biomarker assigned 74% of the bipolar patients
to the major depression group, while 83% of the ﬁrst-episode psychosis patients and 77% and 61% of the individuals with an
ultra-high risk and low-risk state, respectively, were labelled with schizophrenia. Our ﬁndings suggest that neuroanatomical
information may provide generalizable diagnostic tools distinguishing schizophrenia from mood disorders early in the course of
psychosis. Disease course-related variables such as age of disease onset and disease stage as well alterations of structural brain
maturation may strongly impact on the neuroanatomical separability of major depression and schizophrenia.
1 Department of Psychiatry and Psychotherapy, Ludwig-Maximilian-University, Germany
2 Department of Psychiatry, University of Basel, Switzerland
3 Department of Psychiatry and Psychotherapy, University of Regensburg, Germany
4 Department of Psychiatry, University Dublin, Trinity College Dublin, Ireland
5 Department of Radiology, Ludwig-Maximilian-University, Munich, Germany
6 Section of Biomedical Image Analysis, Department of Radiology, University of Pennsylvania, USA
doi:10.1093/brain/awv111 BRAIN 2015: 138; 2059–2073 | 2059
Received February 3, 2015. Revised February 26, 2015. Accepted February 28, 2015. Advance Access publication May 2, 2015
 The Author (2015). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved.
For Permissions, please email: journals.permissions@oup.com
Correspondence to: Nikolaos Koutsouleris,






Keywords: multivariate pattern classiﬁcation; imaging; schizophrenia; mood disorders; at-risk mental states for psychosis
Abbreviations: ARMS = at-risk mental state; BrainAGE = Brain Age Gap Estimation; CV = cross-validation; FEP = ﬁrst episode
psychosis; PANSS = Positive and Negative Symptom Scale; RAVENS = regional analysis of brain volumes in normalized space
Introduction
Psychiatric diagnoses arise from complex clinical processes
and hence are prone to errors (Freedman et al., 2013), de-
pending on the patient’s symptoms, the interviewer’s ex-
perience and the classiﬁcation systems’ normative validity.
Biological data so far only served the exclusion of somatic
pathologies, leaving the question whether individualized
differential diagnosis could beneﬁt from the analysis of
complex neurodiagnostic ‘patterns’ unanswered (Fu and
Costafreda, 2013; Perkins et al., 2014). Furthermore, pat-
tern analysis could unveil overlaps between and heterogen-
eity within diagnoses, thus promoting the revision of
psychiatric nosology, and ultimately the convergence of
neuroscientiﬁc and clinical observation (Krystal and State,
2014).
Phenomenological heterogeneity particularly characterizes
schizophrenic psychoses and mood disorders (Murray
et al., 2005; Linscott and Os, 2010): affective symptoms
are a core feature of prodromal (Schultze-Lutter et al.,
2007; Addington et al., 2014) and established schizophre-
nia (Baynes et al., 2000; Marengo et al., 2000; Chemerinski
et al., 2008; Romm et al., 2010; Cotton et al., 2012;
So¨nmez et al., 2013) while psychotic symptoms frequently
coalesce with mania and depression (Ohayon and
Schatzberg, 2002; Goodwin and Jamison, 2007). At the
brain level, heterogeneity appears as subgrouping and
cross-nosological effects, including neuroanatomical correl-
ates of different symptom dimensions (Koutsouleris et al.,
2008; Nenadic et al., 2012; Zhang et al., 2014), overlap-
ping and segregating structural abnormalities (Bora et al.,
2008, 2010; Yu et al., 2010; Du et al., 2012; Hulshoff Pol
et al., 2012) and gradual transitions of brain activation
patterns between diagnostic entities (Brandt et al., 2014).
Clinically, this heterogeneity may contribute to diagnostic
uncertainty along the diversity of possible disease trajectories
(Baca-Garcia et al., 2007; Pope et al., 2013; Salvatore et al.,
2013). Scientiﬁcally, it challenged the detection of diagnostic-
ally speciﬁc neurobiological markers and hence
questioned the validity of the current disease taxonomy
(Linscott and Os, 2010; Keshavan and Brady, 2011), suggest-
ing that unipolar depression, bipolar disorder and schizo-
phrenia may represent ‘stages’ or ‘domains’ along a
phenotypic and neurobiological disease continuum (Ha¨fner
et al., 2005; Green et al., 2009; Lin et al., 2013).
To simultaneously address this debate and close the
‘translational gap’ between neurobiological ﬁndings and
their clinical application, researchers increasingly used
multivariate pattern analysis to quantify the sensitivity, spe-
ciﬁcity and generalizability of diagnostic brain signatures
(Bray et al., 2009; Fu and Costafreda, 2013) rather than
describing them in terms of their constituents’ group-level
signiﬁcance (Davatzikos, 2004). Using multivariate pattern
analysis, the ﬁeld recently demonstrated a high separability
of different neuropsychiatric conditions versus healthy con-
trols, thus foreshadowing a potential translation of neuroi-
maging ﬁndings into diagnostic tools (Orru` et al., 2012;
Kambeitz et al., 2015). However, doubts remain whether
multivariate pattern analysis-based biomarkers are really
useful in discriminating neuropsychiatric illness from
mental well-being, or whether they are rather needed as
objective tools for a more reliable ‘differential diagnosis’
(Savitz et al., 2013). Initial ﬁndings suggest that neuroima-
ging may aid in individually separating schizophrenia from
bipolar disorder (Schnack et al., 2014) and major depres-
sion (Ota et al., 2013) or bipolar from unipolar depression
(Moura˜o-Miranda et al., 2012; Grotegerd et al., 2013;
Serpa et al., 2014). However, as these studies focused on
pairwise comparisons it remains unclear how the reported
neurodiagnostic signatures would perform in patients with
‘intermediate’ phenotypes and early disease states as well as
in populations broadly covering the different age windows
of these phenotypes.
An established approach to measure how clinical inter-
sections, disease stages and age windows impact on neuro-
diagnostic performance is to investigate these variables
along a single disease dimension, which is ﬁrst spanned
by ‘extreme’ or clearly distinct clinical phenotypes and
then applied to the ‘intermediate’ or moderating conditions.
This approach has been used in the dementia ﬁeld where
morphometric patterns distinguishing patients with
Alzheimer’s disease from healthy controls were used to
quantify disease progression and severity in patients with
mild cognitive impairment (Davatzikos et al., 2009). In the
psychosis ﬁeld, Fan et al. (2008b) used this framework to
trace the neuroanatomical schizophrenia signature in
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unaffected ﬁrst-degree relatives of patients with schizophre-
nia, indicating that the latter display intermediate neuro-
anatomical phenotypes between patients and controls.
Herein, we took a similar approach to explore the hypoth-
esis that the neuroanatomical signatures of major depres-
sion, bipolar disorder, the at-risk mental states for
psychosis (ARMS) and schizophrenia lie along a single dir-
ection spanned by major depression and schizophrenia as
the two end points of this continuum. Therefore, we ﬁrst
measured the single-subject separability of stable schizo-
phrenia versus major depression in a representative data-
base of 262 patients using MRI-based multivariate pattern
analysis and then quantiﬁed differential diagnostic scores of
independent persons with high-risk or ﬁrst-episode states of
psychosis (n = 112) as well as patients with bipolar disorder
(n = 35). Second, we evaluated whether neurodiagnostic
classiﬁcation was moderated by important variables such
as age of disease onset, disease stage and ‘accelerated
ageing’ effects (Koutsouleris et al., 2013) as well as cross-
sectional psychopathological proﬁles overlapping between
major depression and schizophrenia. We expected classiﬁ-
cation performance to be moderated by gradients of neuro-
anatomical schizophrenia likeness increasing (i) from at-risk
states to established schizophrenia; (ii) from major depres-
sion, over bipolar disorder to schizophrenia; and (iii) from
later to earlier disease onsets across the life span.
Materials and methods
Participants
Patients with schizophrenia and major depression were exam-
ined at the Department of Psychiatry and Psychotherapy,
Ludwig-Maximilian-University Munich (LMU) using the
Structured Clinical Interview for DSM-IV – Axis I & II
Disorders (SCID-I/-II), the review of records and psychotropic
medications and a semi-standardized assessment of the psychi-
atric and somatic history. Patients’ symptoms were evaluated
using standard psychometric scales (Table 1). Patients received
a consensus diagnosis by two experienced psychiatrists at
study inclusion and were excluded in case of an unstable
SCID diagnosis over a 4-year follow-up period. Further exclu-
sion criteria were: (i) a history of (a) schizoaffective and/or
bipolar disorder, (b) traumatic brain injury with loss of con-
sciousness, mental retardation, anorexia nervosa, delirium, de-
mentia, amnestic disorders, personality disorders, substance
dependence, as deﬁned by DSM-IV, (c) previous electroconvul-
sive treatments, and (d) somatic conditions affecting the CNS;
as well as (ii) insufﬁcient knowledge of German, IQ 570, and
age 518 or 465. Eleven patients with major depression ful-
ﬁlled criteria for psychotic depression (DSM-IV: 296.24/.34).
Psychotic psychopathology in the major depression group was
further quantiﬁed by computing a composite Z-score from the
Hamilton Depression Rating Scale items ‘feelings of guilt’,
‘hypochondriasis’, ‘depersonalization and derealization’ and
‘paranoid symptoms’. This score was signiﬁcantly elevated in
patients with psychotic major depression [psychotic major de-
pression: mean (SD) = 1.2 (1.0); non-psychotic major
depression: 0.2 (0.9); T = 4.5, P5 0.001]. In the schizophre-
nia group the severity of depressive symptoms was measured
by summing the Positive and Negative Symptom Scale (PANSS
items) ‘somatic concern’, ‘anxiety’, ‘guilt feelings’ and ‘depres-
sion’ and Z transforming this PANSS depression subscale score
(Kontaxakis et al., 2000; El Yazaji et al., 2002).
Patients with an illness duration of 51 year, no previous
inpatient treatment and 512 months (life-time) psychophar-
macological treatment (antipsychotics in schizophrenia, anti-
depressants in major depression) were assigned to ﬁrst
episode subgroups, or to recurrently-ill (recurrent episode)
samples, if they did not fulﬁl these criteria. These ﬁrst episode
criteria were chosen to mitigate potential secondary disease
effects (e.g. continuous medication and frequent hospitaliza-
tion) on brain structure in the respective major depression
and schizophrenia subgroups. Illness duration was the time
between MRI scanning and disease onset deﬁned retrospect-
ively by the onset of symptoms paralleled by a general decline
in social and role functioning (Lieberman et al., 2001).
Following these deﬁnitions, the mean (SD) illness duration in
the major depression/schizophrenia (MDFE/SZFE) samples was
0.34 (0.24)/0.37 (0.68) years, while the respective values for
the MDRE/SZRE were 9.19 (8.22)/7.25 (7.14) years. Diagnosis
had no signiﬁcant main (F = 1.53, P = 0.217) or interaction
effects (F = 1.63, P = 0.203) on illness duration in the ﬁrst epi-
sode and recurrent episode samples.
The schizophrenia versus major depression classiﬁer was in-
dependently validated in 23 patients with ﬁrst episode psych-
osis (FEP) (Yung et al., 1998) recruited at the Department of
Psychiatry, University of Basel and 89 ARMS individuals
pooled across the Ludwig-Maximilian-University (LMU;
n = 52) and Basel (n = 37) early recognition services, which
were detailed in previous work (Koutsouleris et al., 2009)
(Supplementary material and Table 1). ARMS individuals
were stratiﬁed into (i) an early ARMS (n = 21) deﬁned either
by predictive basic symptoms or a Global Functioning-Trait
criterion; and (ii) late ARMS (ARMS, n = 68) deﬁned by atte-
nuated or brief limited intermittent psychotic symptoms, which
closely corresponded to internationally established high-risk
criteria (Yung et al., 1998; Klosterko¨tter et al., 2001).
Psychosis developed in 4.8% and 47.1% of early ARMS and
late ARMS individuals, respectively, over a follow-up period of
4.5 years (n = 33, 87.9% diagnosed as schizophrenia). At
MRI, 61% and 95% of FEP and ARMS individuals, respect-
ively, were antipsychotic-naı¨ve (FEP: six with antipsychotic
treatment for 51 month, and three for 1–3 months; ARMS:
four treated with low-dose atypical antipsychotics for 53
weeks). The diagnosis of patients with FEP was evaluated 5
years after baseline and all examined subjects met DSM-IV
criteria for schizophrenic psychosis.
Furthermore, classiﬁer validation involved 35 patients from
LMU with an established SCID diagnosis of bipolar disorder
(Table 1), who did not meet exclusion criteria i(b)–(d) and ii.
Thirty and ﬁve of these patients fulﬁlled criteria for bipolar I
and II disorder, respectively, with bipolar I patients showing
depressive (n = 11), manic (n = 12), mixed episodes (n = 3) and
euthymic states (n = 4). Psychotic episodes were present in six
patients with bipolar I (four and two patients with manic and
depressive states, respectively).
Finally, 437 healthy volunteers previously described in
Koutsouleris et al. (2013) and scanned at the same Munich
scanner as the patient cohorts were used to correct the
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patients’ MRI data for age and sex effects as detailed below.
The study was approved by each centre’s local ethics commit-
tee. Written informed consent was obtained from each partici-
pant before inclusion.
MRI data acquisition and
preprocessing
Study participants were scanned using two SIEMENS
MAGNETOM VISION 1.5T scanners located at the
University Hospital Basel and the Department of Radiology,
Ludwig-Maximilian-University. In Basel, a T1-weighted 3D
volumetric spoiled gradient recalled echo sequence generated
176 contiguous slices using the following protocol: echo time
4ms; repetition time, 9.7ms; ﬂip angle, 12; ﬁeld of view,
25.6  25.6 cm, matrix, 200  256; voxel dimensions,
1.28  1.0  1.0mm. In Munich, a T1-weighted 3D-
MPRAGE sequence was used: echo time, 4.9ms; repetition
time, 11.6ms; ﬁeld of view, 230mm; matrix, 512  512;
126 contiguous axial slices; voxel dimensions, 0.45  0.45 
1.5mm. No calibration of MRI scanners was performed before
or during the recruitment period.
MRI preprocessing ﬁrst involved the segmentation of T1-
weighted images into grey and white matter as well as CSF
using the VBM8 toolbox (Koutsouleris et al., 2013;
Supplementary material) (Gaser, 2009). Then, the high-
dimensional DRAMMS (Ou et al., 2011, 2014) algorithm
registered each grey matter map to the single-subject MNI
template. Resulting deformations and warped tissue maps
were used to compute grey matter maps for a Regional
Analysis of brain Volumes in Normalized Space
(GM-RAVENS) (Davatzikos et al., 2001).
Correction for age and sex effects
To remove age- and sex-related differences between patient
groups while retaining disease-associated neuroanatomical
variation, the following strategy (Dukart et al., 2011) was
used. First, we calculated voxel-level -coefﬁcients for age
and sex in our healthy control subjects’ GM-RAVENS maps
using partial correlation analysis. These coefﬁcients described
maps of (i) grey matter volume change from 18- to 65-year-old
healthy control subjects; and (ii) grey matter volume differ-
ences between male and female healthy control subjects.
Then we residualized the patient data using these coefﬁcients
to correct for age- and sex effects not attributable to disease-




We implemented a fully automated machine learning pipeline
that extracted neuroanatomical features from the GM-
Table 1 Sociodemographic and clinical characteristics of study groups
Sociodemographic and clinical variables Training and cross-validation database Independent validation database
MD SZ T P BIP FEP ARMS-E ARMS-L
n 104 158 35 23 21 68
n Basel [%] / Munich [%] 0 / 100 0 / 100 0 / 100 100 / 0 0 / 100 54 / 46
Mean age at baseline [yrs] (SD) 42.3 (12.0) 30.8 (10.0) 8.1z 5.001 39 (9.6) 26.8 (6.5) 25.6 (5.6) 24.6 (5.9)
Sex (male) [%] 50 74 15.8† 5.001 51 74 48 68
Handedness (right) [%] 95 91 1.5† ns 85 78 81 90
BMI [kg/m2] (SD) 24.7 (4.6) 24.3 (4.4) 0.7z ns 25.6 (3.6) – 21.1 (2.4) 23.0 (3.3)m
Schooling [yrs] (SD) 10.6 (2.0) 10.6 (2.1) 0.2z ns 11.6 (1.6) 10.0 (1.6) 11.5 (2.9) 11.1 (1.5)
Nicotine [cig./day] 9.7 (13.4) 13.2 (13.7) 1.96z ns 11.4 (13.1) – 7.0 (9.9) 7.0 (9.8)m
Alcohol [g/day] 11.2 (21.1) 11.2 (25.5) 0.01z ns 5.6 (20.6) – 2.9 (5.6) 7.7 (15.3)m
Mean age of disease onset [yrs] (SD; median) 36.5 (12.0) 25.5 (8.0) 8.1z 5.001 26.1 (9.1) – – –
Mean illness duration [yrs] (SD) 6.0 (7.8) 4.5 (7.0) 1.4z ns 13.9 (9.2) – – –
Current treatment with typical antipsychotics [%] 10.0 30.7 17.7† 5.001 0.0 0.0 – –
Current treatment with atypical antipsychotics [%] 9.0 67.3 86.7† 5.001 40.0 39.1 – –
Current chlorpromazine equivalents [mg/d] 43.1 (162.0) 346.3 (373.4) 8.6z 5.001 189.2 (322.9) 244.0 (163) – –
Current treatment with antidepressants [%] 73.1 7.9 156.7† 5.001 16.7 21.7 23.8 12.9
Current treatment with mood stabilizers [%] 13.0 3.3 8.1† 5.01 66.7 0.0 0.0 0.0
Current treatment with lithium [%] 7.0 0.0 10.† 5.01 16.7 0.0 0.0 0.0
Mean BPRS (SD) – 52.7 (13.6) – 41.9 (10.6)b
Mean PANSS total (SD) – 52.6 (29.2) – – – – 56.8 (14.0) 62.0 (22.2)
Mean PANSS positive (SD) – 11.9 (8.0) – – – – 9.86 (2.6) 13.7 (4.5)
Mean PANSS negative (SD) – 15.2 (9.7) – – – – 14.9 (6.7) 15.7 (8.5)
Mean PANSS general psychopathology (SD) – 25.6 (16.1) – – – – 32.0 (7.9) 32.6 (11.1)
Mean SANS (SD) – 45.0 (26.8) – – – 10.0 (5.3) – 9.5 (5.4)b
Mean HDRS (SD) 21.3 (9.5) – – – 9.7 (9.8) – – –
Mean YMRS (SD) 11.0 (12.0) – – –
BrainAGE [yrs] (SD) 4.0 (6.2) 6.0 (6.0) 2.55z 5.05 3.8 (6.5) 5.1 (8.5) 1.5 (7.7) 2.7 (6.8)
Descriptive analyses between major depression and schizophrenia patient groups were performed by means of 2-tests for categorical data (†) and t-tests for continuous data (z) t-
tests. BMI = body mass index; BPRS = Brief Psychiatric Rating Scale; cig.= cigarettes; HDRS = Hamilton Depression Rating Scale; SD = standard deviation; YMRS = Young Mania Rating
Scale. m data only available for the Munich subjects. b data only available for the Basel subjects.
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RAVENS maps and generated decision rules from these fea-
tures to individually distinguish patients with major depression
from those with schizophrenia. To strictly separate the training
process from the evaluation of the classiﬁer’s generalizability,
the pipeline was embedded into a repeated, double cross-
validation (CV) framework (Filzmoser et al., 2009)
(Supplementary material), as detailed previously (Koutsouleris
et al., 2012; Borgwardt et al., 2013). More speciﬁcally, the
following analysis steps were wrapped into a 10  10-fold
cross-validation cycle at the outer (CV2) and the inner (CV1)
levels of repeated double CV: the training subjects’ GM-
RAVENS maps were initially corrected for age and sex effects
(see above) and then scaled voxel-wise to [0, 1]. To reduce the
maps’ dimensionality and discard noisy information, principal
component analysis (PCA) (Hansen et al., 1999) projected
correlated voxel sets to 170 uncorrelated eigenvariates, thus
retaining 80% of the variance in each CV1 training partition.
Correction, scaling, and PCA parameters were applied to the
CV1 test data. Then, in each training partition, PCA features
entered a recursive feature elimination algorithm (Guyon et al.,
2002) that used a linear support vector machine (Fan et al.,
2008a) to remove those eigenvariates that impaired separabil-
ity on the respective CV1 test data (support vector machine
penalty parameter: C = 1).
This process was repeated for all CV1 partitions, thus creat-
ing 100 diagnostic models for each CV2 partition. To obtain
CV2 test predictions, the respective GM-RAVENS data were
ﬁrst processed using the correction, scaling and PCA param-
eters of each CV1 training partition, and then classiﬁed using
the learned decision rules. Classiﬁcation produced decision
scores measuring the neuroanatomical schizophrenia versus
major depression likeness of a given subject. Finally, a CV2
test case’s group membership was predicted by an ensemble
classiﬁer that averaged the decision scores of those 1000 CV1
base learners in the repeated double CV, in which the subject
had not been involved in the training process (Supplementary
material). The bipolar disorder, FEP, early ARMS and late
ARMS samples were processed identically to the CV2 test sub-
jects. Finally, the classiﬁer’s decision function was visualized in
Fig. 3 and the underlying patterns of volumetric differences
were quantiﬁed in Supplementary Fig. 7.
Testing differential diagnostic
gradients in the ARMS and
patient cohorts
The decision scores generated by the differential diagnostic
classiﬁer entered ANOVAs that tested the hypotheses of neuro-
anatomical schizophrenia likeness increasing (i) from the major
depression, through the bipolar disorder, to the schizophrenia
group; and (ii) from the early ARMS, through the late ARMS
to the FEP sample. In case of signiﬁcant omnibus test statistics
(P50.05), post hoc tests were carried out to evaluate pairwise
differences at P5 0.05, corrected for multiple comparisons
using Tukey’s HSD test (Fig. 1). Furthermore, a supplementary
analysis was carried out in the ARMS sample to explore
whether neurodiagnostic scores predicted a subsequent transi-
tion to psychosis (Supplementary material) or functional out-
come as measured by the Global Assessment of Functioning
Score at follow-up (Supplementary Fig. 5).
Testing clinical and brain structural
moderators of neurodiagnostic
classification
Potential moderating effects of disease stage on classiﬁcation
performance were evaluated at P50.05 by stratifying major
depression and schizophrenia patients into ﬁrst episode versus
recurrent episode subgroups and performing a 2 test on the
misclassiﬁcation error in these samples. Then, the impact of
age of onset and BrainAGE (Brain Age Gap Estimation)
(Koutsouleris et al., 2013) on decision scores was investigated
by median-splitting the schizophrenia and major depression
groups according to the latter two variables. Main and inter-
actions effects between decision scores and the factors
‘Diagnosis’, ‘Early versus Late onset’, ‘Low versus High
BrainAGE’ were assessed at P5 0.05 using the General
Linear Model (Table 3 and Fig. 2A). Further analyses evalu-
ated if classiﬁcation of early-onset/high-BrainAGE patients
versus late-onset/low-BrainAGE patients equalled diagnostic
categorization (Fig. 2B and C). Based on these analyses, we
assessed the separability within and between onset-deﬁned
diagnostic subgroups by performing pairwise support vector
machine analyses as described above (Table 2 and
Supplementary Fig. 6).
We explored potential moderating effects of psychometric
psychosis on neurodiagnostic classiﬁcation in major depression
by comparing the decision scores of patients with high (n = 17)
versus low (n = 16) scores on the standardized composite scale
of Hamilton-Depression-Rating Scale items 2, 15, 19 and 20.
These major depression subgroups were identiﬁed by thresh-
olding the composite scale at Z4 1 and Z5 1. The same
procedure was used to measure the effect of psychometric de-
pression on neurodiagnostic classiﬁcation in schizophrenia:
identical Z thresholds were applied to the standardized
PANSS depression subscale and neuroanatomical decision
scores were compared between the resulting schizophrenia sub-
groups with high (n = 30) and low (n = 20) depression scores.
Finally, correlations between the decision scores and additional
clinical variables of the major depression and schizophrenia
samples were analysed in Supplementary Table 1. This supple-
mentary analysis also explored whether neurodiagnostic scores
were associated with verbal IQ in a subgroup of patients with




Schizophrenia and major depression patient groups did not
differ regarding handedness, BMI, schooling years, nicotine
or alcohol consumption (Table 1). Patient groups differed in
the prescribed antipsychotic, antidepressant and mood-stabi-
lizing medications. However, all of these variables had no
effect on neurodiagnostic decision scores (Supplementary
Table 1). Group-level differences were observed for age at
scan, sex and age of disease onset, but not illness duration.
Finally, schizophrenia patients had a higher mean (SD)
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BrainAGE score of + 5.99 (6.00) compared to patients with
major depression [ + 4.04 (6.19)].
Neuroanatomical classification and
influence of moderating variables
The MRI classiﬁer diagnosed unseen major depression and
schizophrenia patients with a balanced accuracy of 76%
(sensitivity/speciﬁcity = 79.8%/72.2%, diagnostic odds
ratio = 10.2; Table 2). Recurrently-ill patients were more
likely misclassiﬁed compared to ﬁrst-episode patients
(error rates MDFE/SZFE: 15.0%/11.5%; MDRE/SZRE:
23.4%/28.8%; 2 = 6.6; P = 0.010). The neuroanatomical
decision function (Fig. 3) involved grey matter reductions
in schizophrenia versus major depression covering the peri-
sylvian structures (inferior frontal, insular, supramarginal,
angular, superior temporal and temporopolar cortices) with
extensions to the orbitofrontal, inferior temporal and
medial temporal cortices. Further reductions covered the
ventromedial prefrontal, anterior cingulate, medial parietal,
occipital and dorsolateral prefrontal cortices. Grey matter
reductions in major depression versus schizophrenia were
localized in a spatially distinct pattern including the brain-
stem regions, cerebellum, periventricular areas and the som-
atosensory cortices, extending to the premotor, parietal and
supplementary motor areas.
The medians of age of onset/BrainAGE used to stratify
patients were 36.3/ + 3.57 in the major depression group
and 23.8/ + 5.62 in the schizophrenia sample. The General
Linear Model evaluating effects of diagnosis, age of onset
and BrainAGE factors on diagnostic scores detected signiﬁ-
cant main effects as well as a signiﬁcant interaction be-
tween the ‘diagnosis’ and ‘early versus late’ factors
(Table 3). Box plot analyses showed that early disease
onset and high BrainAGE increased schizophrenia likeness
in both disease groups, with this effect being more pro-
nounced in major depression compared to schizophrenia
(Fig. 2A). Using the diagnostic decision scores, late-onset,
low-BrainAGE patients were separable from early-onset,
Figure 1 Box plot comparison and ANOVAs of support vector machine (SVM) decision values. Box plot includes the major
depression (MD) and schizophrenia (SZ) training database (light grey) and independent validation data consisting of bipolar disorder (BIP), ARMS
(early, E and late, L) and FEP samples (dark grey). Box plots describe decision value distributions in terms of 5%, 25%, 50%, 75% and 95%
confidence intervals. Frequency of schizophrenia-positive diagnosis is measured as percentage of subjects per group labelled as schizophrenia by
the classifier (top of the box plot chart). P-values of post hoc comparisons in both ANOVAs are provided below and were corrected for multiple
comparisons using Tukey’s HSD method (SPSS version 20, IBM Inc.).
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Figure 2 Box plot and receiver operator characteristics analyses comparing the separability of diagnosis-based versus age of
onset and BrainAGE-based patient groups. (A) Effects of age of onset (left; early, EO and late, LO) and BrainAGE (right) on diagnostic
separability in major depression (MD) versus schizophrenia (SZ) patients. (B) Diagnostic separability of diagnostic groups (major depression
versus schizophrenia, left) versus separability in cross-nosological patient groups (right) defined by early versus late disease onset and high versus
low BrainAGE (Br + versus Br ). (C) Receiver operator characteristics analyses of MRI-based decision scores in the classification of diagnosis
(left) and EO/Br + versus LO/Br groups. SVM = support vector machine; AUC = area under the curve.
MRI biomarker parts functional psychoses BRAIN 2015: 138; 2059–2073 | 2065
high-BrainAGE patients to a similar degree [area under the
curve (AUC) = 0.77] as major depression from schizophre-
nia patients (AUC = 0.80, Fig. 2B and C). Finally, the
onset-stratiﬁed subgroup classiﬁcation showed (i) a better
separability of early versus late-onset major depression pa-
tients (balanced accuracy = 83.7%) than early versus late-
onset schizophrenia patients (62.3%, Table 2); and (ii) a
particularly low separability of early-onset major depres-
sion versus late-onset schizophrenia patients (57.4%).
When diagnostic subgroup probabilities were collapsed
into major depression versus schizophrenia diagnoses, the
balanced accuracy was lower (72.2%) than in the original
whole-group analysis.
The comparison of the neurodiagnostic scores in schizo-
phrenia patients with high versus low psychometric depres-
sion scores [mean (SD): 0.59 (1.30) versus 0.57 (0.98)]
did not yield signiﬁcant differences (T = 0.04; P = 0.966).
Similarly, major depression patients with high psychometric
psychosis scores did not signiﬁcantly differ from patients
with low scores [mean (SD): 1.64 (1.41) versus 0.77
(1.17); T = 1.88; P = 0.071]. Additionally, major depression
patients with versus without a DSM-IV diagnosis of psych-
otic depression did not differ in their neurodiagnostic
scores [1.25 (1.63) versus 0.84 (1.24); T = 0.98;
P = 0.331] or in their misclassiﬁcation rates (20.0%
versus 20.2%; 2 = 0.00; P = 1.000). Finally, increasing
neurodiagnostic schizophrenia likeness in patients with
early-onset schizophrenia was signiﬁcantly associated with
lower verbal IQ (r = 0.46, P = 0.013), whereas this correl-
ation was not observed in late-onset schizophrenia
(r = 0.03, P = 0.906; see Supplementary material).
Presence of a schizophrenia-like
neuroanatomical signature in ARMS,
FEP and bipolar disorder subjects
Decision scores obtained from the independent validation
data showed that schizophrenia likeness was most
pronounced in the Basel FEP patients (86.9% labelled as
schizophrenia, Fig. 1) followed by the cross-centre late
ARMS group (77.9%) and the Munich early ARMS
sample (61.0%). Schizophrenia likeness was lower in the
Munich bipolar disorder group (25.7%) resulting in 74%
of these patients being classiﬁed as having major depres-
sion. Signiﬁcant group differences were detected in all pair-
wise post hoc contrasts of the major depression versus
bipolar disorder versus schizophrenia comparison (Fig. 1).
In the early ARMS versus late ARMS versus FEP analysis,
we observed a signiﬁcant increase of schizophrenia likeness
in the late ARMS compared to the early ARMS group
(P = 0.042) with the former being on par with the FEP
sample (P = 1.000). Finally, we did not ﬁnd signiﬁcant dif-
ferences between subsequent converters versus non-
converters to psychosis. However, increasing schizophrenia
likeness at baseline predicted the ARMS individuals’ GAF
scores at follow-up with R2 = 0.204 (P = 0.018,
Supplementary Fig. 5).
Discussion
This is to our knowledge the ﬁrst structural MRI study to
report a cross-validated, single-subject separability of 76%
in a representative cohort of patients with a stable diagno-
sis of either schizophrenia or major depression. This ﬁnding
is in keeping with the balanced accuracy of 78% reported
by Ota et al. (2013) who examined 25 age-matched female
patients with schizophrenia or major depression using frac-
tional anisotropy and grey matter volumes in predeﬁned
regions of interest. We observed that neuroanatomical mar-
kers successfully generalized to patients with ﬁrst-episode
psychosis who were examined at an independent centre
using a different MRI protocol and were prospectively
diagnosed with schizophrenia. Validation also showed
that diagnostic sensitivity extended to the ARMS and
grew with symptomatic proximity to overt psychosis.
Strikingly, the neurodiagnostic classiﬁer assigned 74% of
Table 2 Diagnostic performance
Dataset TP TN FP FN Sens [%] Spec [%] BAC [%] FPR [%] PPV [%] NPV [%] DOR
Cross-validation 83 114 44 21 79.8 72.2 76.0 27.8 65.4 84.4 10.2
MD [ + 1] versus SZ [1]
Age-of-onset stratified
multi-group classifier
MD-E versus SZ-E 38 51 24 14 73.1 68.0 70.5 30.2 61.3 78.5 5.8
MD-E versus MD-L 42 45 7 10 80.8 86.5 83.7 13.5 85.7 81.8 27.0
MD-E versus SZ-L 31 42 34 21 59.6 55.3 57.4 44.7 47.7 66.7 1.82
SZ-E versus MD-L 67 52 0 8 89.3 100.0 94.7 0.0 100.0 86.7 –
SZ-E versus SZ-L 47 47 29 28 62.7 61.8 62.3 38.2 61.8 62.7 2.72
MD-L versus SZ-L 46 64 12 6 88.5 84.2 86.3 15.8 79.3 91.4 40.9
MD versus SZ (collapsed) 79 104 47 25 76.0 68.9 72.4 31.1 62.7 80.6 6.99
The performance of the MRI diagnostic system was evaluated by means of sensitivity (Sens), specificity (Spec), balanced accuracy (BAC), false positive rate (FPR), positive/negative
predictive value (PPV / NPV) and Diagnostic Odds Ratio (DOR). These measures were calculated from the confusion matrix containing the number of true positives (TP), false
negatives (FN), true negatives (TN) and false positives (FP). MD-E = early-onset major depression; MD-L = late-onset major depression; SZ-E = early-onset schizophrenia; SZ-
L = late-onset schizophreia.
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Figure 3 Voxel probability map (VPM) of reliable contributions to the major depression versus schizophrenia decision
boundary. Voxels with a probability of450% were overlaid on the single subject MNI template using the MRIcron software package (http://www.
mccauslandcenter.sc.edu/mricro/mricron/). Methodological descriptions on how the voxel probability maps were computed can be found in the
Supplementary material. MD = major depression; SZ = schizophrenia.
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patients with bipolar disorder to the major depression
group, suggesting that schizophrenia may be differentiated
from mood disorders at the single-subject level. In addition,
we did not ﬁnd evidence that neurodiagnostic classiﬁcation
was signiﬁcantly inﬂuenced by the presence of psychotic
symptoms in major depression or depressive symptoms in
schizophrenia patients, nor by life-style factors or different
medications at the time of MRI scanning (Supplementary
Table 1). However, we identiﬁed a neuroanatomical signa-
ture shared by schizophrenia and major depression patients
with an average disease onset at 26.5 years (Supplementary
Table 2) and accelerated brain ageing effects (Koutsouleris
et al., 2013), which led to a ‘non-separability’ of these
subgroups.
Our ﬁndings partly agree with recent studies that used
structural imaging data (Ota et al., 2013) or near-infrared
spectroscopy (Takizawa et al., 2014) to differentiate be-
tween functional psychoses at the single-subject level.
However, comparability to these studies is limited because
we did not mitigate naturally occurring demographic dif-
ferences between schizophrenia and major depression by
studying matched patient samples. Instead, we adjusted
our data using a representative database of healthy controls
that fully covered the age range of our patient population
(Dukart et al., 2011). Therefore, potential confounds like
divergent illness durations and equalized sex distributions
were avoided a priori. This approach facilitated the evalu-
ation of the neurodiagnostic pattern, its presence in partly
overlapping clinical phenotypes and its clinical moderators
across the adult life span. First, we identiﬁed a pattern of
perisylvian, prefrontal and temporo-limbic grey matter
volume reductions used by the classiﬁer to separate schizo-
phrenia from major depression at the single-subject level.
Similar patterns were repeatedly described to distinguish
patients with schizophrenia from healthy controls (Honea
et al., 2005; Bora et al., 2011) and were interpreted in line
with a disconnection syndrome (Friston, 1999) underlying
the cognitive, perceptual and thought disturbances of
psychosis (Modinos et al., 2012; Sans-Sansa et al., 2013).
Our ﬁnding of a grey matter volume ‘reduction’ signature
(Supplementary Fig. 7) in schizophrenia compared to major
depression patients, who were on average 11.5 years older,
adds to the concept of schizophrenia being a neurodevelop-
mentally-mediated, cognitive illness (Kahn and Keefe,
2013) marked by more unfavourable disease outcomes
compared to unipolar depression (Harrow et al., 2000).
In contrast, somatosensory, periventricular and subcortical
abnormalities distinguished major depression from schizo-
phrenia in line with previously reported structural abnorm-
alities in major white matter tracts of depressed patients
(Disabato et al., 2014; Guo et al., 2014). Alterations of
these regions may subserve core features of depression,
such as psychomotor and mood disturbances (Seraﬁni
et al., 2011).
Second, the high rate of major depression classiﬁcations
in our bipolar disorder sample suggests that bipolar dis-
order and unipolar depression share a common structural
denominator different from schizophrenia, in line with
Kraepelin’s original dichotomic concept of functional psy-
choses (Kraepelin, 1899). This ﬁnding agrees with initial
Table 3 Moderators of MRI-based differential diagnosis
Data set E SE 95%-CI Low / Up F P
Main effects
MD versus SZ [mean difference] 1.49 0.13 1.24 / 1.75 134.0 _.001
MD [marginal mean] 0.89 0.10 0.70 / 1.09
SZ [marginal mean] 0.60 0.08 0.76 / 0.44
Early versus late-onset 1.03 0.13 1.29 / 0.78 62.6 _.001
Early-onset 0.37 0.09 0.55 / 0.19
Late-onset 0.66 0.09 0.48 / 0.85
Low versus High BrainAGE 0.41 0.13 0.15 / 0.67 9.8 .002
Low BrainAGE 0.35 0.09 0.17 / 0.53
High BrainAGE 0.06 0.09 0.24 / 0.13
Two-way interaction effects
MD versus SZ  Early versus Late-Onset 8.3 0.004
MD  Early-Onset 0.19 0.14 0.09 / 0.47
MD  Late-Onset 1.59 0.14 1.32 / 1.88
SZ  Early-Onset 0.93 0.12 1.16 / 0.70
SZ  Late-Onset 0.27 0.12 0.50 / 0.04
MD versus SZ  Low versus High BrainAGE 3.7 0.056
MD  Low BrainAGE 1.22 0.14 0.95 / 1.50
MD  High BrainAGE 0.56 0.12 0.29 / 0.84
SZ  Low BrainAGE 0.52 0.12 0.74 / 0.29
SZ  High BrainAGE 0.68 0.12 0.91 / 0.44
Main and two-way interaction effects of diagnosis, early versus late disease onset and low versus high BrainAGE on diagnostic scores were analysed using univariate linear modelling in
SPSS (version 20, IBM Inc.). E = estimate (mean difference or marginal mean); SE = standard error; 95%-CI Low/Up = 95% confidence interval with lower and upper bounds; F = F-
statistic; MD = major depression; SZ = schizophrenia.
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reports of a good single-subject separability of schizophre-
nia and bipolar disorder based on structural (Schnack
et al., 2014) or functional MRI (Costafreda et al., 2011).
It may also point to an increased sensitivity of multivariate
pattern analysis techniques in detecting points of rarity in
high-dimensional neuroimaging data compared to univari-
ate methods, which frequently reported considerable over-
laps between bipolar disorder and schizophrenia (Arnone
et al., 2009). On the other hand, we found a signiﬁcant
difference in the neurodiagnostic scores of the major de-
pression and bipolar disorder groups (Fig. 1), which adds
to the growing evidence for structural and functional brain
signatures separating these two largely overlapping condi-
tions (Almeida and Phillips, 2013; Redlich et al., 2014).
However, it remains unclear whether the conﬁguration of
schizophrenia, bipolar disorder and major depression found
in our neuroanatomical analysis is conserved in functional
neuroimaging domains. Hence, future studies are needed
that simultaneously acquire structural and functional ima-
ging data from larger samples of bipolar and schizoaffective
patients and directly quantify the neurodiagnostic
separability of these ‘intermediate’ phenotypes in the
multi-modal imaging space (Lawrie et al., 2011). This
will provide us with a comprehensive picture of continuities
and discontinuities in the functional psychoses spectrum
(Laursen et al., 2009).
Third, we found that an ‘earlier disease occurrence’ cor-
related with lower differential diagnostic accuracy, render-
ing major depression patients with earlier disease onsets
inseparable from schizophrenia patients—despite distinct
cross-sectional phenotypes. This observation was corrobo-
rated by the high separability of age of onset-deﬁned major
depression samples (83.7%, Table 2) compared to the re-
spective schizophrenia subgroups (62.3%), which suggests
that neuroanatomical surrogates of depressive syndromes
strongly covary with the disease onset axis. This hypothesis
has recently received support from studies showing a pro-
nounced thinning in prefrontal, cingulate, precuneal and
inferior temporal cortices of early versus late-onset major
depression patients and healthy controls (Truong et al.,
2013) (Supplementary Fig. 6). Hence, our results may
point to more disrupted neurodevelopmental processes in
early depression, potentially manifesting as an accelerated
brain ageing effect (Koutsouleris et al., 2013). These pro-
cesses may also be linked to a more severe clinical pheno-
type of depression, entailing greater illness severity, higher
relapse rates, more cognitive disturbances, as well as overall
poorer disease outcomes and higher familial co-aggregation
with schizophrenia (Maier et al., 1993; Zisook et al., 2004;
Dekker et al., 2007; Korten et al., 2012). Hence, the over-
laps between schizophrenia and early-onset depression may
lead to a diagnostic dilemma, particularly in the early
phases of these illnesses when overt psychotic symptoms
have not yet evolved or patients are not explored during
psychotic phases. Our results indicate that this challenge
cannot be resolved by our neuroanatomical classiﬁer,
which would frequently diagnose these early-onset
depressed patients with schizophrenia. Thus, it remains to
be elucidated whether different imaging modalities and
combinations thereof may help increase the diagnostic spe-
ciﬁcity in the neurobiological classiﬁcation of early-onset
depression.
Fourth, we observed an increasing schizophrenia likeness
from the early ARMS to the FEP individuals, suggesting
that the neurodiagnostic ﬁngerprint of schizophrenia is al-
ready detectable in persons with basic symptoms, and fur-
ther intensiﬁes as attenuated, brief limited intermittent and
frank psychotic symptoms emerge. This ﬁnding agrees with
previous studies reporting longitudinal grey matter volume
changes in the ARMS, indicating a progressive course of
neuroanatomical alterations as the at-risk state evolves into
overt psychosis (Koutsouleris et al., 2010; Cannon et al.,
2015). However, due to the cross-sectional design of our
study, it remains unclear (i) whether the increase of schizo-
phrenia likeness along these early states of psychosis also
occurs at the level of neuroanatomical disease trajectories;
and (ii) which protective factors contribute to a non-
conversion to psychosis despite the presence of the schizo-
phrenia-speciﬁc pattern in a given patient. Beyond the
arbitrary clinical endpoint of disease transition [see
Supplementary material and Yung et al. (2010)], our sup-
plementary results indicate that an increased schizophrenia
likeness in the ARMS may be associated with poorer func-
tional outcomes at follow-up, suggesting that the identiﬁed
MRI pattern may not only have differential diagnostic val-
idity but also potential prognostic relevance.
Finally, one caveat has to be considered when interpret-
ing our ﬁndings: different medication and treatment his-
tories in our schizophrenia versus major depression
groups may have inﬂuenced the separability of our patients
as long-standing antipsychotic treatment has been previ-
ously shown to interact with disease-related brain changes
(Ho et al., 2011). Although life-time medication data were
not available for the current data set, the high diagnostic
sensitivity in our minimally-treated ARMS and FEP groups
argues against major treatment effects on our results.
Furthermore, our ﬁnding of a signiﬁcantly higher classiﬁca-
tion performance in ﬁrst-episode compared to recurrently-
ill patients is at odds with the expectation that relapsing
illness stages and—in consequence—accumulating disease-
speciﬁc treatment effects would increase the neuroanatom-
ical gaps between schizophrenia and unipolar depression.
The higher diagnostic error in the recurrently-ill patient
sample could be interpreted as a ‘dilution effect’, which
may arise from increasing neuroanatomical heterogeneity
as patients evolve along divergent disease trajectories.
Hence, this heterogeneity may result from (i) structural
brain variation linked to differential disease courses
(Mourao-Miranda et al., 2012) and treatment outcomes
(Palaniyappan et al., 2013); (ii) distinct neuroanatomical
correlates of positive, negative, disorganized and depressive
subsyndromes of schizophrenia, as revealed by factor ana-
lytic studies (Koutsouleris et al., 2008; Nenadic et al.,
2010, 2012; Zhang et al., 2014); and (iii) temporal shifts
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of these proﬁles over time, with negative and depressive
symptoms becoming increasingly prominent in the course
of the disease (Salvatore et al., 2013). Nevertheless, our
results did not support a moderating or ‘diluting’ effect of
depressive/psychotic syndromes in schizophrenia/major de-
pression on neurodiagnostic classiﬁcation performance.
Thus, the strong impact of longitudinal disease variables
such as age of disease onset and disease stage may suggest
that the identiﬁed neuroanatomical biomarker is linked to
the temporal and neurodevelopmental characteristics of
these clinical phenotypes rather than to their cross-sectional
psychopathological features (Gogtay et al., 2011).
In summary, our ﬁndings partly conﬁrm and partly ques-
tion the Kraepelinian dichotomy of functional psychoses
into schizophrenia and affective disorders. This is not sur-
prising if one considers the plethora of studies in support of
either a phenomenological and neurobiological continuum
or a division between these two nosological groups
(Kotov et al., 2013). Our results suggest that the diagnostic
boundaries drawn by a neuroanatomical disease signature
become increasingly porous as patients develop depressive
disorders at younger ages, potentially mediated by a cross-
nosological disruption of neurodevelopmental processes.
This gradient of diagnostic uncertainty does not only chal-
lenge clinical and biomarker-based diagnosis, it highlights
also the utility of pattern recognition methods to probe the
neurological basis of psychiatric illnesses and potentially
reﬁne nosological disease constructs.
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